Company: RNAC
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001453687-25-000099
Chunk: 23

Company: Cartesian Therapeutics, Inc.
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 1
Chunk 23
---
Item 1. Financial Statements (unaudited)

Cartesian Therapeutics, Inc. and Subsidiaries

Consolidated Balance Sheets

(Amounts in thousands, except share data and par value)

 June 30,December 31, 20252024Assets  Current assets:  Cash and cash equivalents$160,324 $212,610 Accounts receivable354 872 Prepaid expenses and other current assets2,717 3,144 Total current assets163,395 216,626 Non-current assets:Property and equipment, net12,285 9,912 Right-of-use asset, net5,164 5,535 In-process research and development assets150,600 150,600 Goodwill48,163 48,163 Long-term restricted cash1,735 1,669 Investments2,000 2,000 Other assets5,551 518 Total assets$388,893 $435,023 Liabilities and stockholders’ deficit  Current liabilities:  Accounts payable$454 $288 Accrued expenses and other current liabilities8,012 12,076 Lease liability3,790 2,851 Contingent value right liability— 7,761 Total current liabilities12,256 22,976 Non-current liabilities:Lease liability, net of current portion9,559 11,133 Warrant liabilities, net of current portion1,364 3,836 Contingent value right liability, net of current portion352,100 387,739 Deferred tax liabilities, net16,141 16,141 Total liabilities391,420 441,825 Commitments and contingencies (Note 17)Stockholders’ deficit:  Series A Preferred Stock, $0.0001 par value; 134,904.563 shares authorized as of June 30, 2025 and December 31, 2024; 120,790.402 shares issued and outstanding as of June 30, 2025 and December 31, 2024— — Series B Preferred Stock, $0.0001 par value; 437,927 shares authorized as of June 30, 2025 and December 31, 2024; 437,927 shares issued and outstanding as of June 30, 2025 and December 31, 2024— — Preferred